S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Laser breakthrough could send stock soaring 2,467% (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
Laser breakthrough could send stock soaring 2,467% (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Laser breakthrough could send stock soaring 2,467% (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
Laser breakthrough could send stock soaring 2,467% (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Laser breakthrough could send stock soaring 2,467% (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
Laser breakthrough could send stock soaring 2,467% (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Laser breakthrough could send stock soaring 2,467% (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
Laser breakthrough could send stock soaring 2,467% (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021

Fate Therapeutics (FATE) Stock Forecast, Price & News

$5.30
-0.17 (-3.11%)
(As of 06/8/2023 ET)
Compare
Today's Range
$5.05
$5.47
50-Day Range
$4.89
$6.59
52-Week Range
$4.02
$37.13
Volume
2.67 million shs
Average Volume
3.18 million shs
Market Capitalization
$521.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
192.5% Upside
$15.50 Price Target
Short Interest
Bearish
31.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.42mentions of Fate Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$274,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.92) to ($2.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

754th out of 986 stocks

Biological Products, Except Diagnostic Industry

120th out of 158 stocks


FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Fate Therapeutics (NASDAQ:FATE) Trading Up 6.7%
[Strong Buy Alert] Is this laser stock in your portfolio?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? There are very few opportunities like this in today's bear market... But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
H.C. Wainwright Remains a Hold on Fate Therapeutics (FATE)
Q1 2023 Fate Therapeutics Inc Earnings Call
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
See More Headlines

FATE Price History

FATE Company Calendar

Last Earnings
5/03/2023
Today
6/08/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
551
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+201.0%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
21 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-171.64%
Pretax Margin
-171.64%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,425,000
Market Cap
$506.66 million
Optionable
Optionable
Beta
1.49

Key Executives

  • Mr. J. Scott WolchkoMr. J. Scott Wolchko (Age 53)
    Founder, CEO, Pres & Director
    Comp: $645k
  • Mr. Edward J. Dulac IIIMr. Edward J. Dulac III (Age 47)
    Chief Financial Officer
    Comp: $455k
  • Ms. Cindy R. TahlMs. Cindy R. Tahl (Age 50)
    Gen. Counsel & Corp. Sec.
    Comp: $455k
  • Dr. Bahram Valamehr Ph.D. (Age 46)
    Chief R&D Officer
    Comp: $455k
  • Dr. Yu-Waye Chu M.D. (Age 55)
    Chief Medical Officer
    Comp: $455k
  • Mr. Jim Beitel M.B.A.
    Sr. VP of Corp. Devel.
  • Dr. Sarah Cooley
    Sr. VP of Clinical Translation
  • Dr. Jerome Bressi Ph.D.
    Sr. VP of Regulatory & Quality
  • Mr. Brian T. Powl M.B.A. (Age 49)
    M.S., Chief Commercial Officer













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

21 Wall Street analysts have issued 1 year target prices for Fate Therapeutics' stock. Their FATE share price forecasts range from $5.00 to $65.00. On average, they anticipate the company's stock price to reach $15.50 in the next year. This suggests a possible upside of 201.0% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 on January 1st, 2023. Since then, FATE shares have decreased by 49.0% and is now trading at $5.15.
View the best growth stocks for 2023 here
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.36. The biopharmaceutical company had revenue of $58.98 million for the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 45.62% and a negative net margin of 171.64%. Fate Therapeutics's revenue for the quarter was up 220.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.68) earnings per share.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (15.07%), BlackRock Inc. (11.66%), Bank of America Corp DE (2.19%), Two Sigma Advisers LP (1.90%), Two Sigma Investments LP (1.83%) and JPMorgan Chase & Co. (1.75%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $5.15.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $506.66 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 551 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -